Evidence map›Paper›PMID 37963105›Full record

ArticleMolecular pharmaceutics2023

Impact of Peptide Sequence on Functional siRNA Delivery and Gene Knockdown with Cyclic Amphipathic Peptide Delivery Agents.

Melissa L Jagrosse, Uday K Baliga, Christopher W Jones, Jade J Russell, Claudia I García, Rauf Ahmad Najar, Arshad Rahman, David A Dean, Bradley L Nilsson

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Melissa L JagrosseDepartment of Chemistry, University of Rochester, Rochester, New York 14627-0216, United States.ORCID 0000-0003-2742-9192
Uday K BaligaDepartment of Pediatrics and Neonatology, University of Rochester Medical Center, School of Medicine and Dentistry, University of Rochester, Rochester, New York 14642, United States.ORCID 0000-0002-4557-8645
Christopher W JonesDepartment of Chemistry, University of Rochester, Rochester, New York 14627-0216, United States.ORCID 0000-0002-2483-2712
Jade J RussellDepartment of Chemistry, University of Rochester, Rochester, New York 14627-0216, United States.ORCID 0000-0003-1414-0904
Claudia I GarcíaDepartment of Chemistry, University of Rochester, Rochester, New York 14627-0216, United States.ORCID 0000-0002-9473-9126
Rauf Ahmad NajarDepartment of Pediatrics and Neonatology, University of Rochester Medical Center, School of Medicine and Dentistry, University of Rochester, Rochester, New York 14642, United States.ORCID 0000-0003-2445-494X
Arshad RahmanDepartment of Pediatrics and Neonatology, University of Rochester Medical Center, School of Medicine and Dentistry, University of Rochester, Rochester, New York 14642, United States.ORCID 0000-0002-5621-0512
David A DeanDepartment of Pediatrics and Neonatology, University of Rochester Medical Center, School of Medicine and Dentistry, University of Rochester, Rochester, New York 14642, United States.ORCID 0000-0001-7748-8073
Bradley L NilssonDepartment of Chemistry, University of Rochester, Rochester, New York 14627-0216, United States.ORCID 0000-0003-1193-3693
University of Rochester · USUniversity of Rochester Medical Center · US

Funding

Cytoplasmic trafficking of non-viral gene therapy vectorsR01EB009903 · NIBIB · UNIVERSITY OF ROCHESTER · PI DEAN, DAVID A · 2009 to 2017
$2.7M
Mitigating Acute Lung Injury by Cell-specific Targeting of MTORR01HL148695 · NHLBI · UNIVERSITY OF ROCHESTER · PI DEAN, DAVID A, RAHMAN, ARSHAD · 2020 to 2023
$2.4M
A multimodal delivery and treatment approach for Acute Lung InjuryR01HL148825 · NHLBI · UNIVERSITY OF ROCHESTER · PI DEAN, DAVID A · 2020 to 2023
$2.3M
Novel Peptide/siRNA Nanoparticles for Treatment of Acute Lung InjuryR01HL138538 · NHLBI · UNIVERSITY OF ROCHESTER · PI DEAN, DAVID A, NILSSON, BRADLEY L. · 2017 to 2020
$2.2M
Matrix-Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF/TOF) Mass SpectrometerS10OD030302 · OD · UNIVERSITY OF ROCHESTER · PI NILSSON, BRADLEY L. · 2021 to 2021
$304k
NHLBI NIH HHS R01 HL138538NHLBI NIH HHS R01 HL148695NHLBI NIH HHS R01 HL148825NIBIB NIH HHS R01 EB009903NIH HHS S10 OD030302
6 · The paper itself

Abstract

Short-interfering RNA (siRNA) oligonucleotide therapeutics that modify gene expression by accessing RNA-interference (RNAi) pathways have great promise for the treatment of a range of disorders; however, their application in clinical settings has been limited by significant challenges in cellular delivery. Herein, we report a structure-function study using a series of modified cyclic amphipathic cell-penetrating peptides (CAPs) to determine the impact of peptide sequence on (1) siRNA-binding efficiency, (2) cellular delivery and knockdown efficiency, and (3) the endocytic uptake mechanism. Nine cyclic peptides of the general sequence Ac-C[XZ]

Indexed as

Cell-Penetrating PeptidesPeptides, CyclicDisulfidesGene Knockdown TechniquesOligonucleotidesRNA, Small InterferingCell-Penetrating PeptidesDisulfidesOligonucleotidesPeptides, CyclicRNA, Small Interferingcell-penetrating peptidecyclic peptidedrug deliverysiRNA delivery

Identifiers

PMID37963105
PMCPMC10698724
OpenAlexW4388667716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.